penta therapeutics limited
penta therapeutics limited Company Information
Company Number
10030535
Next Accounts
Nov 2025
Shareholders
patricia manuela de souza
derek william gilroy
Group Structure
View All
Industry
Management consultancy activities (other than financial management)
Registered Address
elthorne gate 64 high street, pinner, middlesex, HA5 5QA
Website
-penta therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PENTA THERAPEUTICS LIMITED at £8.6k based on a Turnover of £24.5k and 0.35x industry multiple (adjusted for size and gross margin).
penta therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PENTA THERAPEUTICS LIMITED at £32 based on an EBITDA of £10 and a 3.02x industry multiple (adjusted for size and gross margin).
penta therapeutics limited Estimated Valuation
Pomanda estimates the enterprise value of PENTA THERAPEUTICS LIMITED at £284 based on Net Assets of £109 and 2.61x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Penta Therapeutics Limited Overview
Penta Therapeutics Limited is a live company located in middlesex, HA5 5QA with a Companies House number of 10030535. It operates in the management consultancy activities other than financial management sector, SIC Code 70229. Founded in February 2016, it's largest shareholder is patricia manuela de souza with a 90% stake. Penta Therapeutics Limited is a young, micro sized company, Pomanda has estimated its turnover at £24.5k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Penta Therapeutics Limited Health Check
Pomanda's financial health check has awarded Penta Therapeutics Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 8 areas for improvement. Company Health Check FAQs
1 Strong
1 Regular
8 Weak
Size
annual sales of £24.5k, make it smaller than the average company (£421.3k)
- Penta Therapeutics Limited
£421.3k - Industry AVG
Growth
3 year (CAGR) sales growth of -34%, show it is growing at a slower rate (10.1%)
- Penta Therapeutics Limited
10.1% - Industry AVG
Production
with a gross margin of 26.1%, this company has a higher cost of product (59.9%)
- Penta Therapeutics Limited
59.9% - Industry AVG
Profitability
an operating margin of 0% make it less profitable than the average company (8.2%)
- Penta Therapeutics Limited
8.2% - Industry AVG
Employees
with 1 employees, this is below the industry average (4)
- Penta Therapeutics Limited
4 - Industry AVG
Pay Structure
on an average salary of £50.1k, the company has an equivalent pay structure (£50.1k)
- Penta Therapeutics Limited
£50.1k - Industry AVG
Efficiency
resulting in sales per employee of £24.5k, this is less efficient (£121k)
- Penta Therapeutics Limited
£121k - Industry AVG
Debtor Days
it gets paid by customers after 138 days, this is later than average (64 days)
- Penta Therapeutics Limited
64 days - Industry AVG
Creditor Days
its suppliers are paid after 185 days, this is slower than average (25 days)
- Penta Therapeutics Limited
25 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Penta Therapeutics Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Penta Therapeutics Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 98.8%, this is a higher level of debt than the average (53.7%)
98.8% - Penta Therapeutics Limited
53.7% - Industry AVG
PENTA THERAPEUTICS LIMITED financials
Penta Therapeutics Limited's latest turnover from February 2024 is estimated at £24.5 thousand and the company has net assets of £109. According to their latest financial statements, we estimate that Penta Therapeutics Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | ||||||||
| Intangible Assets | ||||||||
| Investments & Other | ||||||||
| Debtors (Due After 1 year) | ||||||||
| Total Fixed Assets | ||||||||
| Stock & work in progress | ||||||||
| Trade Debtors | 9,319 | 4,241 | 30,098 | 41,946 | 56,642 | 18,799 | 3,780 | 20,465 |
| Group Debtors | ||||||||
| Misc Debtors | ||||||||
| Cash | ||||||||
| misc current assets | ||||||||
| total current assets | 9,319 | 4,241 | 30,098 | 41,946 | 56,642 | 18,799 | 3,780 | 20,465 |
| total assets | 9,319 | 4,241 | 30,098 | 41,946 | 56,642 | 18,799 | 3,780 | 20,465 |
| Bank overdraft | ||||||||
| Bank loan | ||||||||
| Trade Creditors | 9,210 | 4,140 | 20,223 | 30,139 | 14,644 | 5,623 | 3,054 | 10,953 |
| Group/Directors Accounts | ||||||||
| other short term finances | ||||||||
| hp & lease commitments | ||||||||
| other current liabilities | ||||||||
| total current liabilities | 9,210 | 4,140 | 20,223 | 30,139 | 14,644 | 5,623 | 3,054 | 10,953 |
| loans | ||||||||
| hp & lease commitments | ||||||||
| Accruals and Deferred Income | 1,200 | |||||||
| other liabilities | ||||||||
| provisions | ||||||||
| total long term liabilities | 1,200 | |||||||
| total liabilities | 9,210 | 4,140 | 20,223 | 30,139 | 14,644 | 5,623 | 3,054 | 12,153 |
| net assets | 109 | 101 | 9,875 | 11,807 | 41,998 | 13,176 | 726 | 8,312 |
| total shareholders funds | 109 | 101 | 9,875 | 11,807 | 41,998 | 13,176 | 726 | 8,312 |
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | ||||||||
| Amortisation | ||||||||
| Tax | ||||||||
| Stock | ||||||||
| Debtors | 5,078 | -25,857 | -11,848 | -14,696 | 37,843 | 15,019 | -16,685 | 20,465 |
| Creditors | 5,070 | -16,083 | -9,916 | 15,495 | 9,021 | 2,569 | -7,899 | 10,953 |
| Accruals and Deferred Income | -1,200 | 1,200 | ||||||
| Deferred Taxes & Provisions | ||||||||
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | ||||||||
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | ||||||||
| Group/Directors Accounts | ||||||||
| Other Short Term Loans | ||||||||
| Long term loans | ||||||||
| Hire Purchase and Lease Commitments | ||||||||
| other long term liabilities | ||||||||
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | ||||||||
| overdraft | ||||||||
| change in cash |
penta therapeutics limited Credit Report and Business Information
Penta Therapeutics Limited Competitor Analysis
Perform a competitor analysis for penta therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in HA5 area or any other competitors across 12 key performance metrics.
penta therapeutics limited Ownership
PENTA THERAPEUTICS LIMITED group structure
Penta Therapeutics Limited has no subsidiary companies.
Ultimate parent company
PENTA THERAPEUTICS LIMITED
10030535
penta therapeutics limited directors
Penta Therapeutics Limited currently has 2 directors. The longest serving directors include Ms Patricia De Souza (Feb 2016) and Professor Derek Gilroy (Feb 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Patricia De Souza | United Kingdom | 53 years | Feb 2016 | - | Director |
| Professor Derek Gilroy | England | 56 years | Feb 2016 | - | Director |
P&L
February 2024turnover
24.5k
+148%
operating profit
10.7
0%
gross margin
26.2%
+0.34%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
February 2024net assets
109
+0.08%
total assets
9.3k
+1.2%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
penta therapeutics limited company details
company number
10030535
Type
Private limited with Share Capital
industry
70229 - Management consultancy activities (other than financial management)
incorporation date
February 2016
age
9
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
February 2024
previous names
dw gilroy consulting limited (June 2024)
accountant
AEQUITAS
auditor
-
address
elthorne gate 64 high street, pinner, middlesex, HA5 5QA
Bank
-
Legal Advisor
-
penta therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to penta therapeutics limited.
penta therapeutics limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PENTA THERAPEUTICS LIMITED. This can take several minutes, an email will notify you when this has completed.
penta therapeutics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
